A multicentre, prospective, randomised controlled trial to assess the safety and effectiveness of cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction the COOL AMI EU Pivotal /

Despite primary PCI (PPCI), ST-elevation myocardial infarction (STEMI) can still result in large infarct size (IS). New technology with rapid intravascular cooling showed positive signals for reduction in IS in anterior STEMI.We investigated the effectiveness and safety of rapid systemic intravascul...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Noc Marko
Laanmets Peep
Neskovic Aleksandar N.
Petrović Milovan
Stanetic Bojan
Aradi Daniel
Kiss Róbert G.
Ungi Imre
Merkely Béla Péter
Hudec Martin
Blasko Péter
Horváth Iván
Davies John R.
Nagy Gergely György
Édes István
et al
Dokumentumtípus: Cikk
Megjelent: 2021
Sorozat:EUROINTERVENTION 17 No. 6
Tárgyszavak:
doi:10.4244/EIJ-D-21-00348

mtmt:32092032
Online Access:http://publicatio.bibl.u-szeged.hu/27908
Leíró adatok
Tartalmi kivonat:Despite primary PCI (PPCI), ST-elevation myocardial infarction (STEMI) can still result in large infarct size (IS). New technology with rapid intravascular cooling showed positive signals for reduction in IS in anterior STEMI.We investigated the effectiveness and safety of rapid systemic intravascular hypothermia as an adjunct to PPCI in conscious patients, with anterior STEMI, without cardiac arrest.Hypothermia was induced using the ZOLL® Proteus™ intravascular cooling system. After randomisation of 111 patients, 58 to hypothermia and 53 to control groups, the study was prematurely discontinued by the sponsor due to inconsistent patient logistics between the groups resulting in significantly longer total ischaemic delay in the hypothermia group (232 vs 188 minutes; p<0.001).There were no differences in angiographic features and PPCI result between the groups. Intravascular temperature at wire crossing was 33.3+0.9°C. Infarct size/left ventricular mass (IS/LV) by cardiac magnetic resonance (CMR) at day 4-6 was 21.3% in the hypothermia group and 20.0% in the control group (p=0.540). Major adverse cardiac events at 30 days increased non-significantly in the hypothermia group (8.6% vs 1.9%; p=0.117) while cardiogenic shock (10.3% vs 0%; p=0.028) and paroxysmal atrial fibrillation (43.1% vs 3.8%; p<0.001) were significantly more frequent in the hypothermia group.The ZOLL Proteus intravascular cooling system reduced temperature to 33.3°C before PPCI in patients with anterior STEMI. Due to inconsistent patient logistics between the groups, this hypothermia protocol resulted in a longer ischaemic delay, did not reduce IS/LV mass and was associated with increased adverse events.
Terjedelem/Fizikai jellemzők:466-473
ISSN:1774-024X